Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | GAPDH | P04406 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18009714 | 0.79 | PI4KA (0.49) | HIF1AGAPDHADORA3SMN1; SMN2DOT1L | |
| SCHEMBL22704695 | 0.79 | HIF1A (0.65) | HIF1AGAPDHADORA3SMN1; SMN2DOT1L | |
| SCHEMBL3297374 | 0.79 | HIF1A (0.65) | HIF1AGAPDHADORA3SMN1; SMN2DOT1L | |
| SCHEMBL13260668 | 0.77 | HIF1A (0.37) | HIF1AGAPDH | |
| SCHEMBL12261152 | 0.76 | ADORA2A (0.47) | HIF1AGAPDHADORA3SMN1; SMN2DOT1L | |
| SCHEMBL2409637 | 0.76 | HIF1A (0.44) | HIF1A | |
| SCHEMBL12261248 | 0.75 | ADORA2A (0.40) | HIF1AGAPDHADORA3SMN1; SMN2DOT1L | |
| SCHEMBL26533906 | 0.75 | ADORA1 (0.40) | ADORA3SMN1; SMN2ADORA2AADORA2BADORA1 | |
| Formycin SCHEMBL14074914 | 0.73 | HIF1A (0.61) | HIF1AGAPDHADORA3SMN1; SMN2DOT1L | |
| Formycin SCHEMBL15262901 | 0.73 | HIF1A (0.61) | HIF1AGAPDHADORA3SMN1; SMN2DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2719701-B1 | Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2719701-A1 | methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES, INC. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010093608-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | HIF1A 2134/4885GAPDH 441/4885ADORA3 1160/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | HIF1A 1871/4885GAPDH 439/4885ADORA3 1149/4885 |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | HIF1A 3588/4885GAPDH 640/4885ADORA3 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.